HaemoAdapt is a decision support application regarding the choice of the most appropriate therapy in hemophilia A and B for each individual patient developed by a prestigious medical team specialized in hematology, based on the 2022 BloodReviews publication ( BloodReviews 52 (2022) 100890) with the scientific endorsement of the Royal Victoria Eugenia Foundation and the collaboration of Novo Nordisk Spain.